News | August 02, 2012

Heart Rhythm Society, ACC Release Expert Consensus on Pacemaker and Mode Selection

Consensus group provides recommendations on mode choices for single- versus dual-chamber devices

August 2, 2012 — The Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) has released the HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection. The expert consensus statement was developed in collaboration with the Society of Thoracic Surgeons (STS), endorsed by the American Heart Association (AHA) and published online as part of the August edition of HeartRhythm, the official journal of the Heart Rhythm Society, as well as the Journal of the American College of Cardiology (JACC). The statement is the first of its kind to specifically address pacemaker device and mode selection, expanding upon the ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities.

The new statement provides a review of the field and reports consensus recommendations on pacemaker device and mode selection. It is a guide to facilitate the appropriate use of single- versus dual-chamber devices for patients who already meet guidelines for pacemaker implantation when a clinical decision for pacing has been made. It includes recommendations for conditions for which there is evidence or general agreement that a given pacing mode is beneficial, useful and effective. This includes conditions for which there is conflicting evidence about the usefulness of a specific pacing mode.

Approximately 400,000 devices are implanted each year in the United States, and there are currently more than three million patients with implanted cardiac devices.[1] Over the past 15 years, multiple randomized trials have compared a number of cardiovascular outcomes among patients randomized to atrial or dual-chamber pacing versus those randomized to ventricular pacing, showing an unmet need for uniform recommendations.

“As new clinical data emerges and technology advances, it is important that clinicians and researchers collaborate to update our knowledge and ensure the best quality of care is delivered,” said co-lead author of the statement, Anne M. Gillis, M.D., FHRS, president of HRS. “This document represents the first recommendations specific to pacing devices and mode selection for the individual patient and provides a framework for clinicians and healthcare administrators to select the best possible therapy to optimize patient outcomes.”

HRS and ACCF convened a panel of 11 cardiac electrophysiologists and surgeons from the United States, Canada and Europe. The writing group reviewed outcomes of pacing mode selection for patients with sinus node dysfunction (SND), atrioventricular (AV) conduction block and other less common indications for pacing. The specific recommendations were based on data derived from multiple randomized clinical trials, single randomized trials, nonrandomized trials, case studies, as well as the expert opinions of the writing group.

Collectively, the consensus experts recommend patients with SND may benefit from atrial or dual-chamber pacing compared with ventricular pacing in regards to the risks of atrial fibrillation (AF), stroke, pacemaker syndrome and improved quality of life. In patients with AV block, dual-chamber pacing can reduce the incidence of pacemaker syndrome and improve some indexes of quality of life. Furthermore, recommending dual chamber pacing or single chamber atrial pacing should not be used in patients in permanent or longstanding persistent AF. Specific recommendations for cardiac resynchronization therapy are not addressed in this document as they are currently provided in previously published guidelines.

For more information: www.heartrhythmjournal.com

 

References:

1. American Heart Association, “Cardiology Patient Page, Pacemaker and Defibrillator Lead Extraction” (Circulation 2011; 123: e378-e380), E. Buch, MD. http://circ.ahajournals.org/content/123/11/e378.full

Related Content

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init